

**To:** (10)(2e) (10)(2e) (10)(2e) (10)(2e) @rivm.nl  
**Cc:** (10)(2e) (10)(2e) (10)(2e) @rivm.nl  
**From:** (10)(2e)  
**Sent:** Wed 5/27/2020 7:44:14 PM  
**Subject:** RE: VEO WP-10 Working Group  
**Received:** Wed 5/27/2020 7:44:15 PM  
[WP9\\_COVIDInputVEO\\_v1.0 \(10\)\(2e\) \(10\)\(2e\) docx](#)

Hi (10)(2e)

Wow things do move fast! \*

See attached file for a few suggestions. Especially with current COVID related work, I see many ethical and legal challenges surrounding the sequencing work. Sequence data can be super useful if it is made available for everyone, and if COMBINED with epidemiological data. But merging (let alone publishing) this data is difficult from a legal perspective, and sharing it quickly with other researchers caused so far only a lot of emotions (but not the data itself...). A legal framework for this would be very helpful.

Best regards,

(10)(2e)

---

**From:** (10)(2e) (10)(2e) (10)(2e) <(10)(2e)> @rivm.nl  
**Sent:** dinsdag 26 mei 2020 08:49  
**To:** (10)(2e) (10)(2e) <(10)(2e)> @rivm.nl  
**Cc:** (10)(2e) (10)(2e) <(10)(2e)> @rivm.nl  
**Subject:** Re: VEO WP-10 Working Group

Hi (10)(2e)

Things already changed from the last time I updated you.

(10)(2e) already sent his questionnaire so we couldn't hook up on it.

Currently we are working on a different questionnaire together with WP9 (Disease X Scenario) to identify barriers to the sharing of COVID-19 data and materials experienced by the Consortium partners.

The project's Kick off Meeting in Thursday and Friday next week and the idea is to present what the Consortium has been doing related to the COVID-19, and that is the approach we are taking for WP10.

See attached the work on the questionnaire so far. We might have a TC to discuss it this week, I will make sure to send you an invitation.

Also let me know if you have any comments on the draft so far.

Kind regards,

(10)(2e)

---

**From:** (10)(2e) (10)(2e)  
**Sent:** Monday, 25 May 2020 20:55:02  
**To:** (10)(2e) (10)(2e) (10)(2e)  
**Cc:** (10)(2e) (10)(2e)  
**Subject:** RE: VEO WP-10 Working Group

Hi (10)(2e)





Van: (10)(2e) (10)(2e) (10)(2e) <(10)(2e)> @rivm.nl>  
 Verzonden: vrijdag 8 mei 2020 17:12  
 Aan: (10)(2e) <(10)(2e)> @cbs.nl>; (10)(2e) <(10)(2e)> @rivm.nl>; (10)(2e) <(10)(2e)> @rivm.nl>; (10)(2e) <(10)(2e)> @ceab.csic.es  
 Onderwerp: VEO WP-10 Working Group

Dear WP10 partners,

Thank you again for the great meeting and valuable additions to the planning of our WP.

Unfortunately, due to time constraints, we were not able to present our WP plans in the VEO bi-weekly meeting today.

But, we are scheduled as the first item in the agenda for the next meeting, potentially on Friday the 22 May.

We want to schedule our next WP10 meeting after this VEO meeting and before the kick off meeting in June, therefore a potential date is on Friday 29 May.

An update from the meeting today, is that the "silent epidemics" scenario, coordinated by (10)(2e) (DTU), is planning to send a questionnaire to the Consortium to assess similar questions from what we had in mind (e.g. which type of data and drivers the case scenarios are planning to include in their assessment).

We mentioned that we would like to add some questions on this assessment. Our plan is to contact (10)(2e) in a separate email, next week, to propose questions and the prioritisation process, and of course use the framework sent by (10)(2e) as a base.

So, it would be very helpful to have your suggestions of questions before the end of next week.

In relation to the question on which platform we can share info/docs for our WP10 group, we believe the VEO share-site to be a good option.

In the share site there is a folder specific to our WP. I added there our presentation with a summary of the points we discussed and agreed on the last meeting.

An important detail is that in this site not only the WP members but everyone in the Consortium can access the documents. We believe that is not a problem, but let us know in case you have any concerns or other suggestions.

If you did not receive an invitation to join the share site from the VEO coordination team, let me know so I can organise that for you.

Finally, see attached the products we promised to share:

- The short description of the VEO case scenarios;
- And the deliverables we have produced for the COMPARE project.

We look forward to working together in WP10.

Best,

(10)(2e) and (10)(2e)

---

**From:** (10)(2e) <(10)(2e)@cbs.nl>  
**Sent:** Thursday, 7 May 2020 17:26  
**To:** (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e)  
**Cc:** (10)(2e)  
**Subject:** Data evaluation criteria

Dear all,

It was nice to meet you today in our call, and we are looking forward to our collaboration in this work package.

As promised during our call, please find below a concise list of general criteria that we use when evaluating new data sources for statistical purposes. For evaluation new sources a context-tailored assessment is made, so the list below is meant to be indicative rather than exhaustive. But nevertheless, it might contain some useful input for the pre-questionnaire.

- . *Data need:* Which stakeholders and interests are at play? Is there already a clearly defined user (internal/external) who requires the data? What is their objective behind using the data? What research questions and intended output is the data necessary for? What potential risks or conflicts of using the data are there that weigh against the need for the data?
- . *Data aspects and quality:* representativeness (selectivity issues, coverage of target population geographically and across time), validity, periodicity (frequency of data points available), accuracy and trustworthiness, security, ethical aspects, data structure and data models, interoperability, linkability (at what level/granularity, with other data, systems, methods etc.)
- . *Technical aspects:* Is it in principle technically possible to access the data? How? What aspects play a role for this (e.g. storage capacity, protection of transport, download options en limitations, remote access or limited to on-site access etc.)?
- . *Legal aspects:* is there a legal mandate and basis to use the data, or are the legal barriers? Does it fit in the mission and work programme? Which general laws and regulation apply, and does using the data comply with these laws and regulations? Which domain-specific legal requirements apply to this particular data? Think along dimensions such as privacy, protection, public availability, GDPR principles such as consent and minimalisation etc., intellectual property, etc.
- . *Business case (for data receiver and supplier):* which (joint) added value and business model can be generated from using the data? What costs are necessary for using the data? What benefits/value can be derived from it? Which risks are associated with using it? How might it impact other work process and outputs besides the primary use scenario? What sort of dependencies emerge from using the data? How sustainable/foreseeable is continued availability of the data?
- . *Practicability:* are the necessary organisational resources available to acquire and use the data (budget, staffing, know-how etc., see also technical aspects)?

We will also follow up with some ideas for relevant questions for the pre-questionnaire.

Best regards,

(10)(2e)

(10)(2e)

Data Officer

CBS | CBS-weg 11 | Postbus 4481 | 6401 CZ Heerlen

T (10)(2e) | (10)(2e) | (10)(2e) [@cbs.nl](mailto:info@cbs.nl)



Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.  
[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

[www.rivm.nl/en](http://www.rivm.nl/en) Committed to health and sustainability